Cell culture processes for the production of viral vectors for gene therapy purposes

被引：17

作者：

Warnock, James N.

Merten, Otto-Wilhelm

Al-Rubeai, Mohamed ^{[1
]}

机构：

[1] Univ Coll Dublin, Sch Chem & Bioproc Engn, Dublin 4, Ireland

[2] Mississippi State Univ, Dept Agr & Biol Engn, Mississippi State, MS 39762 USA

[3] Genethon, F-91002 Evry, France

来源：

CYTOTECHNOLOGY | 2006年 / 50卷 / 1-3期

关键词：

adeno-associated virus; adenovirus; bioreactor; culture conditions; herpes simplex virus vectors; lentivirus; microcarrier; optimization; process development; retrovirus;

D O I：

10.1007/s10616-005-5507-z

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Gene therapy is a promising technology for the treatment of several acquired and inherited diseases. However, for gene therapy to be a commercial and clinical success, scalable cell culture processes must be in place to produce the required amount of viral vectors to meet market demand. Each type of vector has its own distinct characteristics and consequently its own challenges for production. This article reviews the current technology that has been developed for the efficient, large-scale manufacture of retrovirus, lentivirus, adenovirus, adeno-associated virus and herpes simplex virus vectors.

引用

页码：141 / 162

页数：22

共 149 条

[1] SPECIFIC MONOCLONAL-ANTIBODY PRODUCTIVITY AND THE CELL CYCLE-COMPARISONS OF BATCH, CONTINUOUS AND PERFUSION CULTURES [J].